Hormonal therapy emerges as a beneficial option for managing patients with estrogen-receptor (ER) positive advanced ovarian cancer [48], a patient subset represented in our study by the ER-expressing cell line OVCAR-3. Here, ESR1 is linked to ovarian carcinoma.